Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
IgE inhibitors
allergy
angioedema
chronic spontaneous urticaria
omalizumab
urticaria
Journal
European journal of dermatology : EJD
ISSN: 1952-4013
Titre abrégé: Eur J Dermatol
Pays: France
ID NLM: 9206420
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
pubmed:
2
12
2020
medline:
25
2
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) not responding to antihistamines. Data on omalizumab use in real-world settings and in different populations are lacking. To record our five-year experience of omalizumab use in patients with refractory CSU in a real-world setting. A retrospective analysis of medical records of 80 patients with refractory CSU was performed. Demographic, and clinical characteristics, patterns of response, discontinuation strategies and rate of recurrence were analysed. Eighty individuals were included. UAS7 and DLQI significantly decreased from baseline. Complete response was achieved in 86.3%. Late response was observed at 27.5% of the patients. After discontinuation, 21.7% of patients reinitiated omalizumab due to relapse. The mean number of omalizumab administrations up to first discontinuation was 6.8 (based on an approach to shorten the treatment interval). Only 15.0% of patients experienced adverse events during treatment. Omalizumab, with long-term management, was highly effective and safe in achieving control of refractory CSU, with more favourable responses compared to Phase III clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) not responding to antihistamines. Data on omalizumab use in real-world settings and in different populations are lacking.
OBJECTIVES
OBJECTIVE
To record our five-year experience of omalizumab use in patients with refractory CSU in a real-world setting.
MATERIALS & METHODS
METHODS
A retrospective analysis of medical records of 80 patients with refractory CSU was performed. Demographic, and clinical characteristics, patterns of response, discontinuation strategies and rate of recurrence were analysed.
RESULTS
RESULTS
Eighty individuals were included. UAS7 and DLQI significantly decreased from baseline. Complete response was achieved in 86.3%. Late response was observed at 27.5% of the patients. After discontinuation, 21.7% of patients reinitiated omalizumab due to relapse. The mean number of omalizumab administrations up to first discontinuation was 6.8 (based on an approach to shorten the treatment interval). Only 15.0% of patients experienced adverse events during treatment.
CONCLUSION
CONCLUSIONS
Omalizumab, with long-term management, was highly effective and safe in achieving control of refractory CSU, with more favourable responses compared to Phase III clinical trials.
Identifiants
pubmed: 33258453
pii: ejd.2020.3919
doi: 10.1684/ejd.2020.3919
doi:
Substances chimiques
Anti-Allergic Agents
0
Omalizumab
2P471X1Z11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM